Brookline Capital Management Estimates Genelux FY2024 Earnings

Genelux Co. (NASDAQ:GNLX) – Equities researchers at Brookline Capital Management issued their FY2024 earnings per share estimates for shares of Genelux in a research report issued to clients and investors on Tuesday, March 25th. Brookline Capital Management analyst K. Dolliver anticipates that the company will post earnings per share of ($0.89) for the year. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q4 2024 earnings at ($0.20) EPS and FY2025 earnings at ($0.70) EPS.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings results on Friday, April 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.07).

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Genelux in a report on Tuesday. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $18.25.

Genelux Trading Up 1.7 %

Shares of NASDAQ GNLX opened at $3.08 on Friday. Genelux has a 1 year low of $1.60 and a 1 year high of $6.50. The firm’s 50-day moving average is $4.06 and its 200-day moving average is $3.10. The firm has a market capitalization of $106.38 million, a PE ratio of -3.24 and a beta of -1.41.

Hedge Funds Weigh In On Genelux

Several institutional investors have recently modified their holdings of GNLX. Virtu Financial LLC acquired a new stake in shares of Genelux in the 4th quarter valued at approximately $25,000. Apollon Wealth Management LLC grew its holdings in Genelux by 20.4% during the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after purchasing an additional 2,857 shares during the period. Raymond James Financial Inc. acquired a new stake in Genelux in the fourth quarter worth $41,000. Brown Brothers Harriman & Co. boosted its position in shares of Genelux by 76.2% during the third quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock worth $50,000 after purchasing an additional 9,114 shares in the last quarter. Finally, D.A. Davidson & CO. bought a new position in shares of Genelux during the fourth quarter worth $51,000. 37.33% of the stock is currently owned by institutional investors and hedge funds.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.